Abbott and Sekisui collaborate to offer coagulation testing for laboratories worldwide

Coagulation tests measure a person’s blood clotting ability, which can help doctors assess risks of excessive bleeding or developing clots

Abbott and Sekisui have signed an agreement to offer coagulation testing solutions for laboratories worldwide. Coagulation tests measure a person’s blood clotting ability, which can help doctors assess risks of excessive bleeding or developing clots. Under the agreement, Abbott will be the exclusive distributor of Sekisui’s new CP3000 coagulation instrument in the US, Europe and other regions that recognize CE Mark.

Coagulation testing helps clinicians in assessing people before many medical treatments and in monitoring those who take medications that can affect clotting. It is also useful in the diagnosis of blood-related disorders, such as hemophilia (when blood does not clot normally) and thrombosis (formation of a clot that blocks blood flow).

Sales of the CP3000 are expected to begin later this year in Europe, countries that recognise CE Mark and non-regulated countries, and in the US in 2016. Abbott will have non-exclusive distribution rights with Sekisui in China, Hong Kong, Japan and Macau.